Korsana Biosciences, Inc. Common Stock
KRSA
33 hedge funds and large institutions have $13.7M invested in Korsana Biosciences, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 5 closing their positions.
15,250% more call options, than puts
Call options by funds: $307K | Put options by funds: $2K
0.96% less ownership
Funds ownership: 48.85% → 47.89% (-0.96%)
3% less funds holding
Funds holding: 34 → 33 (-1)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
25% less capital invested
Capital invested by funds: $18.3M → $13.7M (-$4.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$4.11K |
| 2 |
Jane Street
New York
|
+$2.15K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.54K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$627 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$591 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$210K |
| 2 |
PCM
Prelude Capital Management
New York
|
-$80K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$17K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$17K |
| 5 |
Renaissance Technologies
New York
|
-$8.43K |
KRSA Hedge Fund Activity: Q4 2022 in Review
33 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q4 2022, worth a combined $13.7M — down 25% from $18.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of KRSA and 4 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 7 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $4.11K. The largest seller was Diametric Capital, exiting entirely with an estimated $210K sold.
- 33 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q4 2022, down from 34 in Q3 2022.
- Funds reported $13.7M of Korsana Biosciences, Inc. Common Stock stock for Q4 2022, down 25% quarter-over-quarter.
- 4 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q4 2022 and 5 closed out, a net change of -1 holder.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q4 2022 was Virtu Financial, an estimated $4.11K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q4 2022 was Diametric Capital, an estimated $210K sold.
Based on aggregated 13F filings for Q4 2022.